URL,EXTRACTED VALUE
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/ipg.html",) with a Reduce citing slowing growth and greater-than-industry deterioration in credit quality.
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/aee.html",") with an Underperform rating and $4 target based on Tysabri uncertainty, bapineuzumab clinical risk, MS competition, and debt overhang."
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/mmc.html",) and
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/qsft.html",") with a Neutral rating and $8 target, citing slowing industry trends and its higher cost balance sheet."
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/lrcx.html",(NASDAQ:
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/usm.html",) with a Buy rating and $19 target. The firm believes the company is well positioned in the Software as a Service category of E-mail Marketing.
"/sdd/edimar/Desktop/doutorado/doutorado04/bases/WEIR/finance/quotes.stocknod.com/oke.html",) with an Outperform rating and $31 target. The firm expects Darden to meet or beat low near-term expectations given solid internal fundamentals.
